Compare OPTT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | PSTV |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 61.1M |
| IPO Year | 2007 | N/A |
| Metric | OPTT | PSTV |
|---|---|---|
| Price | $0.34 | $0.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.50 | ★ $7.25 |
| AVG Volume (30 Days) | 3.7M | ★ 5.0M |
| Earning Date | 12-15-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,748,000.00 | ★ $5,258,000.00 |
| Revenue This Year | $70.98 | $1.73 |
| Revenue Next Year | $106.21 | $12.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.16 |
| 52 Week High | $1.75 | $2.31 |
| Indicator | OPTT | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 46.97 |
| Support Level | $0.30 | $0.54 |
| Resistance Level | $0.38 | $0.60 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 27.61 | 17.72 |
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).